← All trials
NCT03463317
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2018
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 1512
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Humboldt UniversityLead sponsor
- German Center for Cardiovascular Research e. V. (DZHK)Collaborator
- Humboldt UniversityReponsible party - principal investigator
- Humboldt UniversityStudy chair
- Atrial Fibrillation NetworkCollaborator
- Stiftung Institut fuer HerzinfarktforschungCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.